Published in Nat Genet on June 28, 2009
A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol (2011) 16.53
Systematic localization of common disease-associated variation in regulatory DNA. Science (2012) 14.47
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
MYC on the path to cancer. Cell (2012) 8.65
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
Super-enhancers in the control of cell identity and disease. Cell (2013) 7.50
Next-generation genomics: an integrative approach. Nat Rev Genet (2010) 5.88
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene (2012) 3.83
Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet (2011) 3.73
Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet (2013) 3.65
Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet (2009) 3.59
Multiplexed massively parallel SELEX for characterization of human transcription factor binding specificities. Genome Res (2010) 3.46
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A (2010) 3.37
Interpreting noncoding genetic variation in complex traits and human disease. Nat Biotechnol (2012) 3.01
Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet (2012) 2.86
Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol (2010) 2.80
Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning. Nat Biotechnol (2015) 2.79
Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet (2013) 2.67
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell (2013) 2.56
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res (2010) 2.24
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders. Cell Cycle (2011) 2.19
Current status of genome-wide association studies in cancer. Hum Genet (2011) 2.14
Architecture of inherited susceptibility to common cancer. Nat Rev Cancer (2010) 2.14
Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res (2013) 2.14
Genetic Control of Chromatin States in Humans Involves Local and Distal Chromosomal Interactions. Cell (2015) 2.11
A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med (2014) 2.08
A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. J Natl Cancer Inst (2010) 2.00
Epidemiologic and genetic aspects of spina bifida and other neural tube defects. Dev Disabil Res Rev (2010) 1.96
HERC2 rs12913832 modulates human pigmentation by attenuating chromatin-loop formation between a long-range enhancer and the OCA2 promoter. Genome Res (2012) 1.96
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
Personalized medicine: new genomics, old lessons. Hum Genet (2011) 1.85
Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res (2014) 1.83
Identification of {beta}-catenin binding regions in colon cancer cells using ChIP-Seq. Nucleic Acids Res (2010) 1.81
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet (2010) 1.78
A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75
Genome-wide association studies and beyond. Annu Rev Public Health (2010) 1.73
Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma (2011) 1.69
Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst (2013) 1.63
A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet (2011) 1.60
Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A (2011) 1.59
Transcriptional enhancers in development and disease. Genome Biol (2012) 1.52
Genome-wide association analyses identify three new susceptibility loci for primary angle closure glaucoma. Nat Genet (2012) 1.51
Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition. Genome Res (2014) 1.49
Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet (2014) 1.48
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet (2010) 1.47
Enhancers: five essential questions. Nat Rev Genet (2013) 1.46
VDR/RXR and TCF4/β-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol (2011) 1.46
Molecular interactions between HNF4a, FOXA2 and GABP identified at regulatory DNA elements through ChIP-sequencing. Nucleic Acids Res (2009) 1.45
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
MYC and metastasis. Cancer Res (2011) 1.43
Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. Hum Mol Genet (2011) 1.42
Maps of open chromatin guide the functional follow-up of genome-wide association signals: application to hematological traits. PLoS Genet (2011) 1.41
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. Proc Natl Acad Sci U S A (2014) 1.39
Genome-wide association studies in cancer--current and future directions. Carcinogenesis (2009) 1.39
Generalizability and epidemiologic characterization of eleven colorectal cancer GWAS hits in multiple populations. Cancer Epidemiol Biomarkers Prev (2010) 1.38
A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers. Proc Natl Acad Sci U S A (2009) 1.37
Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome Res (2012) 1.35
Positive regulation of c-Myc by cohesin is direct, and evolutionarily conserved. Dev Biol (2010) 1.34
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res (2012) 1.33
TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions. Proc Natl Acad Sci U S A (2010) 1.32
Genetic heterogeneity in colorectal cancer associations between African and European americans. Gastroenterology (2010) 1.31
Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. PLoS Genet (2010) 1.29
The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front Genet (2012) 1.28
Replication study of SNP associations for colorectal cancer in Hong Kong Chinese. Br J Cancer (2010) 1.24
Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene (2015) 1.22
Genetic architecture of ambulatory blood pressure in the general population: insights from cardiovascular gene-centric array. Hypertension (2010) 1.22
Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. BMC Cancer (2010) 1.22
Mapping of disease-associated variants in admixed populations. Genome Biol (2011) 1.21
You Don't Muck with MYC. Genes Cancer (2010) 1.20
Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med (2014) 1.19
Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat Commun (2015) 1.19
GWAS3D: Detecting human regulatory variants by integrative analysis of genome-wide associations, chromosome interactions and histone modifications. Nucleic Acids Res (2013) 1.18
Allele-specific expression of TGFBR1 in colon cancer patients. Carcinogenesis (2010) 1.17
GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis (2012) 1.16
Genome-wide mechanisms of nuclear receptor action. Trends Endocrinol Metab (2009) 1.16
Genome-wide epigenetic data facilitate understanding of disease susceptibility association studies. J Biol Chem (2012) 1.15
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Layers of epistasis: genome-wide regulatory networks and network approaches to genome-wide association studies. Wiley Interdiscip Rev Syst Biol Med (2010) 1.15
HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. J Clin Invest (2014) 1.14
Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol (2010) 1.13
Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level. Genome Biol (2010) 1.12
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer (2015) 1.10
Maps of open chromatin highlight cell type-restricted patterns of regulatory sequence variation at hematological trait loci. Genome Res (2013) 1.10
Laying a solid foundation for Manhattan--'setting the functional basis for the post-GWAS era'. Trends Genet (2014) 1.10
Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. Hum Mol Genet (2014) 1.08
Amplitude modulation of androgen signaling by c-MYC. Genes Dev (2013) 1.08
Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. Gastroenterology (2014) 1.08
Chromosome 8q24-Associated Cancers and MYC. Genes Cancer (2010) 1.07
Myc: the beauty and the beast. Genes Cancer (2010) 1.07
Notch dimerization is required for leukemogenesis and T-cell development. Genes Dev (2010) 1.06
No effect of cancer-associated SNP rs6983267 in the 8q24 region on co-expression of MYC and TCF7L2 in normal colon tissue. Mol Cancer (2009) 1.06
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Wnt signaling and cancer. Genes Dev (2000) 18.53
ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature (2009) 18.38
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
Model-based analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci U S A (2006) 13.68
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet (2007) 11.62
Linking colorectal cancer to Wnt signaling. Cell (2000) 11.58
Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet (2007) 9.88
A common genetic risk factor for colorectal and prostate cancer. Nat Genet (2007) 7.11
Biological function of unannotated transcription during the early development of Drosophila melanogaster. Nat Genet (2006) 6.20
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Myc deletion rescues Apc deficiency in the small intestine. Nature (2007) 5.42
In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet (2003) 5.10
The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res (2000) 2.62
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res (2008) 2.43
Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet (2008) 2.41
A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS. Proc Natl Acad Sci U S A (2003) 2.19
Mapping chromatin interactions by chromosome conformation capture. Curr Protoc Mol Biol (2006) 1.95
Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res (2003) 1.49
NMPP: a user-customized NimbleGen microarray data processing pipeline. Bioinformatics (2006) 1.30
Development and evaluation of real competitive PCR for high-throughput quantitative applications. Anal Biochem (2005) 1.27
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Demonstrating stratification in a European American population. Nat Genet (2005) 9.49
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med (2012) 9.17
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Colorectal cancer. Lancet (2010) 8.36
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med (2006) 7.82
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
A common genetic risk factor for colorectal and prostate cancer. Nat Genet (2007) 7.11
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
The ecoresponsive genome of Daphnia pulex. Science (2011) 6.55
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered (2003) 5.78
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
Germline competent embryonic stem cells derived from rat blastocysts. Cell (2008) 5.52
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet (2006) 4.78
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
A genomewide admixture map for Latino populations. Am J Hum Genet (2007) 4.71
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Merging and emerging cohorts: not worth the wait. Nature (2007) 4.66
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol (2012) 4.47
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered (2003) 4.34
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med (2004) 4.09
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04